Covid-19 manufacturing roundup: Ritonavir production to reach 100M doses annually; Schumer calls for a boost to domestic vaccine supply
Amid the spike in positive Covid-19 cases thanks to the Omicron variant, Ascletis will expand its production of the oral tablet ritonavir to produce 100 million doses a year. And the company is ready to increase that number if the market calls for that.
ASC10 targets RNA dependent RNA polymerase, while ASC11 targets 3-chymotrypsin-like protease. Ascletis currently owns the only authorized ritonavir tablet in China, which was approved in September. A low dose ritonavir oral tablet (100mg) is a component of Paxlovid, Pfizer’s drug that recently landed a contract with the Belgian government for 10,000 courses.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
